lung cancer or bronchial carcinoma
Conditions
Interventions
first cycle of chemotherapy for lung cancer. Patients were already scheduled
for this treatment after staging work-up.
NSCLC: cisplatin/gemcitabin
SCLC: cisplatin/etoposide
Sponsors
Medisch Centrum Leeuwarden
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -Informed consent is obtained. -newly diagnosed adenocarcinoma or squamous cell carcinoma stage IIIA, IIIB or IV or small cell lung cancer) -Adults 18-80 years. -scheduled for chemotherapy as first part of the treatment: Cisplatin/Gemcitabine (NSCLC) and Cisplatin/Etoposide (SCLC)
Exclusion criteria
Exclusion criteria: -Previous chemotherapy -unable to evaluate response with the RECIST criteria. -unable to follow the instructions for the eNose measurement -eating, drinking and smoking
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Difference in smellprints of exhaled breath provided by the eNose before and after chemotherapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| -ad a: difference in smellprints of exhaled breath provided by the eNose between distinct subgroups of lung cancer (adenocarcinoma vs sqamous cell carcinoma vs SCLC) -ad b: relationship between smellprints and stage of lung cancer or SUV on 18FDG-PET (see objectives). -ad c: relationship between smellprints and tumour response classified according to the RECIST [3] criteria | — |
Countries
Netherlands
Outcome results
None listed